(Reuters) – Top executives at U.S. pharmaceutical company Novavax Inc aren’t waiting to see how well their COVID-19 vaccine works before they reap the financial rewards. Only peers at rival biotech company Moderna Inc have sold more stock than Novavax executives among major firms that received U.S. taxpayer funding to develop or manufacture COVID-19 vaccines, … Continue reading Yahoo News: Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way